An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.

By R. Benza, Dave P. Miller, R. Barst, D. Badesch, A. Frost, M. McGoon. Chest, 2012

1,030 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/142e2417017a4cbbdfbe7837a08c6447264ae7f4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. G. Simonneau
2. N. Galiè

Citations in the corpus

• Riociguat for the treatment of pulmonary arterial hypertension. (2013, background): “Gastroesophageal reflux disease 4 (3) 14 (6) 4 (6)”
• Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. (2015, background): “Disease progression 10 (4) 16 (6) 12 (10) 4 (3)”
• Unremarkable AI: Fitting Intelligent Decision Support into Critical, Clinical Decision-Making Processes (2019, background): “Unfortunately, many patients who received VADs die shortly after the implant [2].”